-
12:55:40 PM
Sign in with email
Forgot your password?
Register with email
Account Verification

LEGN Stock News

05/26/22 3:10 AM
Nasdaq : LEGN
CARVYKTI® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Legend Biotech Corporation, a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that the European Commission has granted conditional marketing authorization of CARVYKTI ® for the treatment of adults with relapsed and refractory multiple myeloma who...
RHEA-AI
very positive
05/18/22 8:30 AM
Nasdaq : LEGN
Legend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma With Updated Data From BCMA CAR-T Studies at 2022 ASCO and EHA
Legend Biotech Corporation, a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that eight company-sponsored abstracts were accepted at the 2022 American Society of Clinical Oncology Annual Meeting and the European Hematology Association’ s 2022 Hybrid...
RHEA-AI
neutral
05/05/22 4:01 PM
Nasdaq : RCKT, LEGN
earnings
Rocket Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals, Inc., a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today reports financial results for the quarter ending March 31, 2022, and updates from the Company’ s key pipeline developments, business operations...
RHEA-AI
neutral
04/21/22 8:30 AM
Nasdaq : LEGN
Legend Biotech Achieves Milestone Under Collaboration Agreement with Janssen Biotech, Inc. for BCMA CAR-T
Legend Biotech Corporation, a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the achievement of a $50 million milestone under its collaboration agreement with Janssen Biotech, Inc. for ciltacabtagene autoleucel, now marketed in the United States under...
RHEA-AI
very positive
03/25/22 8:01 AM
Nasdaq : LEGN
CARVYKTI® (ciltacabtagene autoleucel) Receives Positive CHMP Opinion for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Legend Biotech Corporation, a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended Janssen Pharmaceutica NV’ s marketing authorization of CARVYKTI ® for the...
RHEA-AI
neutral
03/25/22 7:50 AM
Nasdaq : LEGN
Janssen Receives Positive CHMP Opinion Recommending CARVYKTI® (Ciltacabtagene Autoleucel) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
The Janssen Pharmaceutical Companies of Johnson& Johnson announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended marketing authorisation of ciltacabtagene autoleucel for the treatment of adults with relapsed and refractory multiple myeloma, who have received at least...
RHEA-AI
positive